This trial aims to evaluate the safety and effectiveness of using the patient's bone marrow stem cells in treating type 2 diabetes. The trial is being conducted by the Peking University Aerospace Centre Hospital in Beijing and expects to enrol 500 patients by May 2015. Participants will be divided into those that require conventional oral treatment for their diabetes and those that also require insulin. Within these categories, participants will be further divided into those that only receive the standard treatment (control groups) and those that receive standard treatment as well as their own bone marrow (experimental groups). Participants will be monitored for complications and for changes in their condition.